Expedite payer coverage with surrogate endpoints

The idea of surrogate endpoints isn’t new, but they have matured with the increased adoption of accelerated pathways for regulatory approval. FDA will grant limited approval, but require confirmatory studies and as a result, sponsors need to prepare data and develop strategies earlier – for both regulators and payers.

Return to Insights Center

Related Insights

Blog

Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Article

Three strategies for articulating a coherent product value story

Dec 18, 2021

Blog

Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

Feb 8, 2022

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Whitepaper

Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022

Webinar

China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022

Blog

Preparing for a new era in European Market Access

Jul 22, 2022

Blog

U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?

Aug 17, 2022

Podcast

Why Rare Disease Therapeutics Need Early Market Access Planning

Jan 4, 2023

Blog

Innovative modeling method could speed patient access to critical IO therapies

Jan 4, 2023

Playbook

Are you using real-world evidence?

Feb 1, 2023